Monoclonal Gammopathy of Undetermined Significance (MGUS)
Symptoms, Doctors, Treatments, Advances & More

Monoclonal Gammopathy of Undetermined Significance (MGUS) Overview

Save information for later
Sign Up

Learn About Monoclonal Gammopathy of Undetermined Significance (MGUS)

What is the definition of Monoclonal Gammopathy of Undetermined Significance (MGUS)?
Monoclonal gammopathy of undetermined significance (MGUS) is a condition in which an abnormal protein called monoclonal protein is detected in the blood. MGUS typically does not cause any problems, although some affected people may experience numbness, tingling or weakness. In some cases, MGUS may progress over time to certain forms of blood cancer (such as multiple myeloma, macroglobulinemia, or B-cell lymphoma). MGUS is thought to be a multifactorial condition that is likely associated with the effects of multiple genes in combination with lifestyle and environmental factors. People with MGUS are usually monitored closely to ensure that the levels of monoclonal protein do not rise and other problems do not develop.
What are the alternative names for Monoclonal Gammopathy of Undetermined Significance (MGUS)?
  • Monoclonal gammopathy of undetermined significance
  • MGUS
Who are the top Monoclonal Gammopathy of Undetermined Significance (MGUS) Local Doctors?
Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Referral may be required

Vince Lombardi Cancer Clinic

2845 Greenbrier Rd, Ste 250, 
Green Bay, WI 
920-288-4180
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Demet Yasar is a Hematologist practicing medicine in Green Bay, Wisconsin. Dr. Yasar is rated as a Distinguished provider by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). She is also highly rated in 51 other conditions, according to our data. Her clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Pleuropulmonary Blastoma, and Myelodysplastic Syndrome (MDS). Dr. Yasar is board certified in American Board Of Internal Medicine, Hematology.

Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Daniel J. Frank
Oncology | Hematology
Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Daniel J. Frank
Oncology | Hematology
Referral may be required
430 Warrenville Road, Suite 300, 
Lisle, IL 
630-364-7850
Experience:
20+ years
Languages Spoken:
English, Spanish
See accepted insurances
Offers Telehealth

Each patient is unique and therapy needs to be tailored to an individual's personal needs and goals. Dr. Frank is rated as a Distinguished provider by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). He is also highly rated in 25 other conditions, according to our data. His clinical expertise encompasses Familial Colorectal Cancer, Anemia, Myelodysplastic Syndrome (MDS), and Monoclonal Gammopathy of Undetermined Significance (MGUS). Dr. Frank is board certified in Hematology & Oncology.

 
 
 
 
Learn about our expert tiers
Learn More
Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Asheesh Shipstone
Hematology | Oncology
Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Asheesh Shipstone
Hematology | Oncology
Referral may be required

Ballad Health Cancer Center

2202 North John B. Dennis Highway, Suite 100, 
Kingsport, TN 
423-578-8500
Languages Spoken:
English
See accepted insurances

Asheesh Shipstone is a Hematologist and an Oncologist practicing medicine in Kingsport, Tennessee. Dr. Shipstone is rated as a Distinguished provider by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). He is also highly rated in 54 other conditions, according to our data. His clinical expertise encompasses Adult Immune Thrombocytopenia, Colorectal Cancer, Hemangioma Thrombocytopenia Syndrome, and Thrombocytopenia. Dr. Shipstone is board certified in American Board Of Internal Medicine.

View All Doctors
What are the latest Monoclonal Gammopathy of Undetermined Significance (MGUS) Clinical Trials?
Phase 2 Dose-Ranging and Interception Study of Linvoseltamab in Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
Phase 2 Dose-Ranging and Interception Study of Linvoseltamab in Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
Enrollment Status: Recruiting
Publish Date: June 15, 2026
Intervention Type: Drug
Study Phase: Phase 2

Summary: This study is researching an investigational drug called linvoseltamab (study drug) in participants at moderate risk of developing multiple myeloma (about 3 to 10% average annual risk), a group that consists of patients with precancerous conditions called High-Risk Monoclonal Gammopathy of Undetermined Significance (HR-MGUS) and Non-High-Risk Smoldering Multiple Myeloma (NHR-SMM). The primary purp...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With Multiple Myeloma (MM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With Multiple Myeloma (MM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
Enrollment Status: Recruiting
Publish Date: June 10, 2026
Intervention Type: Biological

Summary: No effective specific treatment is currently available for the management of Multiple Myeloma (MM) and Monoclonal Gammopathy of Undetermined Significance (MGUS). A better understanding of the pathophysiological mechanisms would make it possible to propose treatments specifically targeting the deregulated pathways.

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center